Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- apomorphine
- Bystolic (nebivolol)
Interactions between your drugs
apomorphine nebivolol
Applies to: apomorphine, Bystolic (nebivolol)
MONITOR CLOSELY: Apomorphine may potentiate the hypotensive effects of vasodilators, antihypertensive agents, or agents with hypotensive properties. Apomorphine alone has been associated with orthostatic hypotension, hypotension, syncope, and dose-dependent decreases in systolic and diastolic blood pressure. In clinical studies of the subcutaneous formulation of apomorphine in patients with advanced Parkinson's disease, hypotension (10% vs 4%), myocardial infarction (3% vs. 1%), serious pneumonia (5% vs. 3%), serious falls (9% vs. 3%), and bone and joint injuries (6% vs. 2%) were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n=94) compared to those not receiving these medications (n=456). Some of these events may be related to the increased incidence of hypotension.
MANAGEMENT: Caution and close monitoring for altered efficacy and safety are recommended if patients receive apomorphine with an antihypertensive agent, vasodilator, or agents with hypotensive properties. Patients should be made aware of the possible side effects (e.g., dizziness, lightheadedness, orthostasis) and be cautioned about driving, operating machinery, or performing other hazardous tasks. They should also be advised to avoid rising abruptly from a sitting or recumbent position and to contact their physician if they experience symptoms of hypotension such as dizziness, lightheadedness, or fainting.
References (5)
- (2022) "Product Information. Apokyn (apomorphine)." US WorldMeds LLC
- (2022) "Product Information. Kynmobi (apomorphine)." Sunovion Pharmaceuticals Inc
- (2023) "Product Information. Dacepton (apomorphine)." Ever Pharma UK Ltd
- (2024) "Product Information. aPomine Intermittent (apomorphine)." Pfizer Australia Pty Ltd, 1.1
- (2024) "Product Information. Movapo (apomorphine)." Stada Pharmaceuticals Australia Pty Ltd
Drug and food interactions
apomorphine food
Applies to: apomorphine
GENERALLY AVOID: Alcohol and apomorphine may have additive hypotensive and sedative effects. Coadministration of 0.6 or 0.3 g/kg of ethanol with apomorphine in healthy subjects resulted in greater decreases in blood pressure compared to apomorphine alone. The mean largest decrease (the mean of each subject's largest drop in blood pressure measured within 6 hours after apomorphine administration) in standing systolic and diastolic blood pressure was 6.7 and 8.4 mmHg, respectively, with apomorphine alone. When coadministered with 0.6 g/kg of ethanol (equivalent to approximately 3 standardized alcohol-containing beverages), the mean largest decrease in standing systolic and diastolic blood pressure was 11.3 and 12.6 mmHg, respectively (standing systolic and diastolic blood pressure decreased by as much as 61 and 51 mmHg, respectively, in this group). When coadministered with 0.3 g/kg of ethanol, the mean largest decrease in standing systolic and diastolic blood pressure was 8.4 and 7.1 mmHg, respectively.
MANAGEMENT: Patients should be advised to avoid consumption of alcohol during apomorphine treatment.
References (5)
- (2022) "Product Information. Apokyn (apomorphine)." US WorldMeds LLC
- (2022) "Product Information. Kynmobi (apomorphine)." Sunovion Pharmaceuticals Inc
- (2023) "Product Information. Dacepton (apomorphine)." Ever Pharma UK Ltd
- (2024) "Product Information. aPomine Intermittent (apomorphine)." Pfizer Australia Pty Ltd, 1.1
- (2024) "Product Information. Movapo (apomorphine)." Stada Pharmaceuticals Australia Pty Ltd
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Sinemet
Sinemet is used to treat symptoms of Parkinson's disease, such as muscle stiffness, tremors ...
Cogentin
Cogentin is used for extrapyramidal reaction, parkinson's disease
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Requip
Requip is used to treat symptoms of Parkinson's disease, such as stiffness, tremors and muscle ...
Mirapex
Mirapex (pramipexole) treats the symptoms of Parkinson's disease and is also used to treat Restless ...
Rytary
Rytary is used to treat symptoms of Parkinson's disease and parkinsonism that may follow carbon ...
Azilect
Azilect (rasagiline) is used to treat the symptoms of Parkinson's disease. Learn about side ...
Crexont
Crexont (carbidopa and levodopa) is an extended-release capsule that may be used to treat symptoms ...
Exelon
Exelon (rivastigmine) is used to treat dementia caused by Alzheimer's or Parkinson's disease ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.